methyl 2-chloro-3-(4-hydroxyphenyl)-propanoate | 60833-61-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 2-chloro-3-(4-hydroxyphenyl)-propanoate
• 英文别名: 2-chloro-3-(4-hydroxyphenyl)propionic acid methyl ester；Methyl 2-chloro-3-(4-hydroxyphenyl)propanoate
• CAS: 60833-61-6
• 化学式: C₁₀H₁₁ClO₃
• 分子量: 214.649
• InChiKey: MQYOUDFBZXCMEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-chloro-3-(4-hydroxyphenyl)-propanoate 在 溴 、 sodium acetate 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 2.0h， 以92%的产率得到2-chloro-3-(3,5-dibromo-4-hydroxyphenyl)propionic acid methyl ester
  参考文献：
  名称：

  [EN] NOVEL PHARMACEUTICAL COMPOSITIONS
  [FR] NOUVELLES COMPOSITIONS PHARMACEUTIQUES

  摘要：

  公开号：

  WO2005094810A3
• 作为产物：
  描述：

  对氨基苯酚 、 丙烯酸甲酯（MA） 在 盐酸 、 sodium nitrite 、 copper(l) iodide 作用下， 以 水 、 丙酮 为溶剂， 反应 0.75h， 生成 methyl 2-chloro-3-(4-hydroxyphenyl)-propanoate
  参考文献：
  名称：

  [EN] NOVEL PHARMACEUTICAL COMPOSITIONS
  [FR] NOUVELLES COMPOSITIONS PHARMACEUTIQUES

  摘要：

  公开号：

  WO2005094810A3

文献信息

• Heterocyclic compounds and their use in the treatment of Type-II diabetes
  申请人：SmithKline Beecham PLC

  公开号：US05589492A1

  公开（公告）日：1996-12-31

  A compound of the formula A.sup.1 --X--(CH.sub.2).sub.n --O--A.sup.2 --A.sup.3 --CO.R.sup.2 (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein: A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; A.sup.2 represents a benzene ring having three optional substituents; A.sup.3 represents a moiety of formula --(CH.sub.2).sub.m --CHR.sup.1 -- wherein R.sup.1 represents a halogen atom or a moiety of formula S(O).sub.p A.sup.4 wherein A.sup.4 represents hydrogen, substituted or unsubstituted alkyl, aryl, aralkyl, alkylcarbonyl or an aromatic heterocyclyl group and p represents zero or an integer 1 or 2 and m represents zero or an integer in the range of from 1 to 5, or A.sup.3 represents a moiety of formula --CH.dbd.CR.sup.1 -- wherein R.sup.1 is as defined above; R.sup.2 represents OR.sup.3 wherein R.sup.3 represents hydrogen, alkyl, aryl or aralkyl, or R.sup.2 represents --NR.sup.4 R.sup.5 wherein R.sup.4 and R.sup.5 each independently represent hydrogen or alkyl or R.sup.4 and R.sup.5 together with the nitrogen atom to which they are attached form a heterocyclic ring; X represents O, S or NR wherein R represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; and n represents an integer in the range of from 2 to 6; a process for the preparation of such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound and composition in medicine.

  一种具有以下结构的化合物：A.sup.1 --X--(CH.sub.2).sub.n --O--A.sup.2 --A.sup.3 --CO.R.sup.2 (I)或其互变异构体和/或其药学上可接受的盐，和/或其药学上可接受的溶剂，其中：A.sup.1代表取代或未取代的芳香杂环基团；A.sup.2代表具有三个可选取代基团的苯环；A.sup.3代表具有式--(CH.sub.2).sub.m --CHR.sup.1 --的基团，其中R.sup.1代表卤素原子或式S(O).sub.p A.sup.4的基团，其中A.sup.4代表氢、取代或未取代的烷基、芳基、芳基烷基、烷基羰基或芳香杂环基团，p代表零或整数1或2，m代表零或范围在1到5之间的整数，或A.sup.3代表具有式--CH.dbd.CR.sup.1 --的基团，其中R.sup.1如上定义；R.sup.2代表OR.sup.3，其中R.sup.3代表氢、烷基、芳基或芳基烷基，或R.sup.2代表--NR.sup.4 R.sup.5，其中R.sup.4和R.sup.5各自独立地代表氢或烷基，或R.sup.4和R.sup.5与它们连接的氮原子一起形成杂环环；X代表O、S或NR，其中R代表氢原子、烷基、酰基、芳基烷基，其中芳基可能是取代或未取代的，或取代或未取代的芳基；n代表范围在2到6之间的整数；一种制备这种化合物的方法，包括这种化合物的药物组合物和这种化合物及组合物在医学中的用途。
• Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll
  申请人：——

  公开号：US20040220147A1

  公开（公告）日：2004-11-04

  This invention relates to novel compounds which are thyroid receptor ligands, preferably antagonists, and to methods for using such compounds in the treatment of cardiac and metabolic disorders, such as cardiac arrhythmias, thyrotoxicosis, subclinical hyperthyrodism and liver diseases.

  本发明涉及一种新型化合物，其为甲状腺受体配体，优选为拮抗剂，并且涉及使用这些化合物治疗心脏和代谢性疾病的方法，例如心律失常、甲状腺毒症、亚临床甲状腺功能亢进和肝脏疾病。
• Novel Pharmaceutical Compositions
  申请人：Garg Neeraj

  公开号：US20080027096A1

  公开（公告）日：2008-01-31

  The invention provides compounds of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, for use in the treatment or prophylaxis of condition mediated by an androgen receptor.

  该发明提供了公式(I)的化合物或其药学上可接受的酯、酰胺、溶剂或盐，包括这种酯或酰胺的盐和这种酯、酰胺或盐的溶剂，用于治疗或预防由雄激素受体介导的疾病。
• [[.omega.-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents
  作者：Barrie C. C. Cantello、Michael A. Cawthorne、Graham P. Cottam、Peter T. Duff、David Haigh、Richard M. Hindley、Carolyn A. Lister、Stephen A. Smith、Peter L. Thurlby

  DOI：10.1021/jm00049a017

  日期：1994.11

  A series of [(ureidoethoxy)benzyl]-2,4-thiazolidinediones and [[(heterocyclylamino)alkoxy]-benzyl]-2,4-thiazolidinediones was synthesized from the corresponding aldehydes. Compounds from the urea series, exemplified by 16, showed antihyperglycemic potency comparable with known agents of the type such as pioglitazone and troglitazone (CS-045). The benzoxazole 49, a cyclic analogue of 16, was a very potent enhancer of insulin sensitivity, and by modification of the aromatic heterocycle, an aminopyridine, 37, was identified as a lead compound from SAR studies. Evaluation of antihyperglycemic activity together with effects on blood hemoglobin content, to determine the therapeutic index, was performed in 8-day repeat administration studies in genetically obese C57 Bl/6 ob/ob mice. From these studies, BRL 49653 (37) has been selected, on the basis of antihyperglycemic potency combined with enhanced selectivity against reductions in blood hemoglobin content, for further evaluation.
• HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF TYPE II-DIABETES
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0635007A1

  公开（公告）日：1995-01-25